Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 phase III trial – AstraZeneca

Written by | 18 Sep 2023

Positive results from the FLAURA2 Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS),… read more.

Alecensa delivers unprecedented phase III results for people with ALK-positive early-stage lung cancer – Roche

Written by | 14 Sep 2023

Roche announced that the Phase III ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis…. read more.

Optimizing tobacco cessation treatment with lung cancer screening

Written by | 29 Aug 2023

Lung cancer is the deadliest cancer in the United States, and 80% of lung cancer deaths are linked to one risk factor: smoking. While lung cancer screenings are… read more.

Nivolumab appears to benefit patients with stage III lung cancer

Written by | 12 Aug 2023

Among patients with resectable stage IIIA or IIIB NSCLC (non–small-cell lung cancer), those treated with neoadjuvant nivolumab plus chemotherapy have achieved a higher level of complete response and… read more.

Survival benefit from frontline immunotherapy in progression-free non–small cell lung cancer peaks at 2 years

Written by | 13 Jun 2023

For patients who are progression-free after two years of frontline immunotherapy for advanced non–small cell lung cancer (NSCLC), there does not appear to be a survival benefit in… read more.

Keytruda + chemotherapy before surgery and continued as a single agent after surgery reduced the risk of event-free survival events by 42% versus pre-operative chemotherapy in resectable Stage II, IIIA or IIIB NSCLC – Merck Inc

Written by | 7 Jun 2023

Merck known as MSD outside of the United States and Canada, announced positive results from the pivotal Phase III KEYNOTE-671 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, as a… read more.

Immuno-oncology treatment pre-surgery safe and effective option for localized non-small cell lung cancer

Written by | 23 Sep 2022

New study data shows that the immuno-oncology drug, atezolizumab (pronounced  a” te zoe liz’ ue mab, marketed as Tecentriq) is a safe and effective treatment for stage IB-IIIB… read more.

Deep learning algorithm may streamline lung cancer radiotherapy treatment

Written by | 17 Sep 2022

Lung cancer, the most common cancer worldwide, is targeted with radiation therapy (RT) in nearly one-half of cases. RT planning is a manual, resource-intensive process that can take… read more.

Phase III IMpower010 study of Tecentriq consistent with previous studies in NSCLC and published in The Lancet – Genentech/Roche

Written by | 8 Feb 2022

Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS)… read more.

Lung cancer – urgent action required to get back on track

Written by | 3 Feb 2022

Two recent reports show how hard lung cancer outcomes have been impacted as a result of the covid-19 pandemic, according to Professor Robert Rintoul, chair of the UK… read more.

Air pollution linked to rise of lung cancer

Written by | 6 Dec 2021

Findings also reveal decline in smoking led to decrease in another type of lung cancer. An international team of scientists, led by Nanyang Technological University, Singapore (NTU Singapore),… read more.

Lung cancer screening for survivors of head and neck cancer

Written by | 11 Nov 2021

Head and neck cancer survivors with long smoking histories had a 2.5-fold greater risk of developing lung cancer than those without prior head and neck cancer, according to… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.